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Boston, MA, USAA B S T R A C TIn recent years drug prices have increasingly become a topic of debate
for patients, providers, payers and policy makers.
To place the current drug price debate into historical context, we
searched the New York Times and Wall Street Journal from 1985 – 2015
and found that concerns about drug prices have commonly featured in
the press over the study period with recently stronger calls for change.
Price levels, types of innovations, stakeholder responses, and
strategies to address high prices discussed in the media suggest thatee front matter Copyright & 2016, International S
r Inc.
.1016/j.jval.2015.10.008
_leopold1@hphc.org.
ndence to: Christine Leopold, Harvard Medical Schconcerted efforts are required to enable affordable and high-value
innovations.
Keywords: drug prices, media, New York Times, US, Wall Street
Journal.
Copyright & 2016, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The introduction of a number of breakthrough, highly effective, and
high-cost specialty medicines over the past few years has stoked the
ﬁre of the long-running drug price debate. The prices of these
specialty medicines—above $100,000 per treatment course—have
resulted in widespread outcry among patients, providers, insurers,
and members of the Congress and the Senate. More such products
will come to the market as 700 specialty products—including
immune therapy and gene therapy—are currently in the drug pipe-
line. But does the recent debate’s renewed vigor signal a watershed
moment? Or is it merely a rehashing of an often-revisited grievance
that will be forgotten as “business as usual” goes on?
To put these questions into historical context, we used Lex-
isNexis Academia—a database of legal, news, and business
sources—to determine how often the New York Times (NYT) and
the Wall Street Journal (WSJ) featured articles including the
term “drug pricing” from January 1985 through 15th of November
2015. We excluded articles covering stories outside of the United
States as well as blog entries. In total we found 926 articles (549 in
the NYT; 377 in the WSJ with a peak of 75 articles from both
journals in 2015) including the term. For the purpose of analyzing
the media releases, we assigned each article to one of four
categories: 1) increase in drug prices, 2) innovation, 3) stake-
holder’s response, and 4) strategies. In the case in which articles
discussed more than one of the topics, we classiﬁed them under
the dominant theme of the article. In Figure 1, we present the data(as number of media releases per 5 years) per category over time to
illustrate how media debate on drug pricing has changed through-
out the past 30 years.Increase in Drug Prices
The concern of increasing drug prices has been a steady topic
over the past 30 years (see Fig. 1: NYT, December 28, 1985).
In the late 1980s, media coverage on high drug prices centered on
the novel AIDS treatment zidovudine (AZT) costing $10,000 per
patient per year. A peak in media coverage is noticeable in the
mid-2000 due to the launch of new cancer medicines such as
bevacizumab (Avastin) for metastatic colon cancer and trastuzumab
(Herceptin) for breast cancer, with a price tag of $100,000 per treat-
ment course. More recently, reported prices have reached a new
high. For example, ivacaftor (Kalydeco), indicated for a rare condition,
cystic ﬁbrosis, is priced upward of $300,000 per patient per year (see
Fig. 1: NYT, March 23, 2008). Since early 2014, media releases are
dominated by the launch of new very effective but at the sometime
very expensive high-volume drugs such as the hepatitis C treat-
ments, with sofosbuvir priced around $84,000 for a treatment
course (see Figure 1: WSJ, April 1, 2014) and more recently the
cholesterol-lowering drugs PCSK9, with Praluent priced around
$14,600 per patient per year. However as those medicines are
indicated for millions of patients their impact on public health
budgets is tremendous and brings a new urgency to the debate.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Burroughs-Wellcome cuts 
price of AZT under 
pressure from AIDS 
activists.
WSJ, Sep 19, 1989
Prices for drugs vary 
widely, study finds.
NYT, Dec 28, 1985
Senate study of drug 
prices could prove a 
bitter pill for 
pharmaceutical makers.
WSJ, Feb 3, 1993
Senator Assails Drug 
Prices: According to a 
Congressional report 
prescripon-drug prices 
jumped by almost 3 mes 
the rate of inﬂaon during 
the ﬁrst half of 1991
NYT,  Sep  25, 1991
New England leaders meet 
to discuss ways to cut 
drug prices.
WSJ,  Dec  17, 1999
Some drugs rise in price at 
fast pace.
NYT, March 16, 1995
Cheap Drugs From 
Canada: Another 
Political Hot Potato.
NYT, Oct 23, 2003
Uninsured elderly 
found to pay higher 
drug prices then 
HMO:.
WSJ, April 10, 2000
When a drug costs 
$300,000.
NYT, March 23, 2008 
Legislation to let 
government negotiate 
drug prices falters.
WSJ, April 19, 2007
Cancer Doctors Offer Way 
to Compare Medicines, 
Including by Cost.
NYT, June 22, 2015
Pharmacy Deal Heralds 
Changed Landscape for 
Hepatitis Drugs.
NYT, December 22, 2014
$1,000-a-day hepatitis C 
drug is rapid blockbuster.
WSJ, April 1, 2014
Sanofi halves price of 
cancer drug Zaltrap after 
Sloan-Kettering rejection.
NYT, Nov 9, 2012
Fig. 1 – Overview of media releases for the term “drug pricing” in the New York Times and the Wall Street Journal (1985–2015).
Notes. We searched LexisNexis for the terms “drug pricing” in the New York Times and theWall Street Journal from January 1985
until 15th of November 2015 (excluding media releases from outside of the United States and blog entries). Figure 1 shows the
number of media releases per content category in 5-year windows. Depicted are either abstracts or full stories in the print or
online versions. Boxes show headlines with short explanations and sources of publications selected to illustrate the changing
media debate on drug prices over time. (Side note: Reported prices are accounted for inﬂation $10,000 in 1985 equals to
$22,299 in 2015.) (Color version of ﬁgure is available online.)
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 1 4 – 1 6 15In addition, most recent concerns about steep increases of
generic prices have dominated the debate on drug pricing.
Repeatedly, it was reported that drug price increases have far
outpaced inﬂation—the most recent estimates report a 75%
increase since 2007 [1]—and that launch prices (adjusted for
inﬂation) of 58 cancer drugs approved between 1995 and 2013
have increased by 10% (about $8.500) per year [2].Innovation
Since 2000, media coverage on the launch of breakthrough
innovations (such as orphan medicines) is increasing. This can
be traced back to the Food and Drug Administration’s approach to
increase access to innovative drugs through regulations such as
priority review, accelerated approval, fast track review, and
breakthrough designations.
These innovations contribute to the drug pricing debate due to
their high prices and the combined volume of their use, impacting
health care budgets. The number of personalized treatments target-
ing speciﬁc genes or the immune system of small numbers of eligible
patients per molecule—like ivacaftor for the treatment of about 2150
patients globally with a speciﬁc variant of cystic ﬁbrosis—is rapidly
increasing: in 2011, molecules were approved for 22 orphan or rare
diseases, each with between 50,000 and 200,000 patients. In addition,
new, costly molecules treating millions of patients (such as the new
hepatitis C medicines and the new cholesterol-lowering products)
are increasingly being launched, leading to heightened concerns
about budget impact and sustainability of systems.Voices in the media are raising the question of why innova-
tions that were developed with funds from the National Institute
of Health (funded by American tax payers’ money) should cost
two to three times more in the United States than in Canada or
Europe (see Fig. 1: NYT, October 23, 2003). In 1995, the National
Institute for Health dropped a provision ensuring that drugs
developed with government funds are sold at reasonable prices
because the clause presumably drove industry away from poten-
tially beneﬁcial scientiﬁc collaborations [2].Stakeholder’s Response
Throughout the past 30 years, high drug prices have been on the
political agenda of senators and of the Congress representing a
politically sensitive topic (see Fig. 1: WSJ, December 17, 1999). In
the 1980s, patients’ voices prompted the pharmaceutical industry
to lower the price of the ﬁrst high-priced HIV drug. In the years to
follow, the voices of retirees, represented by the American
Association of Retired Persons, advocated for the implementation
of the Medicare Part D drug beneﬁt and are reﬂected in media
coverage peaks between 2000 and 2004 (see Fig. 1: WSJ, April 10,
2000). Most recently, however, responses to high-cost medicines
seem to be changing, with new stakeholders taking action: in
2012, clinicians at a major cancer center have declined using a
new cancer chemotherapy due to its price (see Fig. 1: NYT,
November 9, 2012); in 2014, Express Scripts, one of the largest
pharmacy beneﬁt managers, announced plans to exclude from its
formulary 70 high-priced medicines that it deemed to be low
value (see Fig. 1: NYT, December 22, 2014); in addition, state
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 1 4 – 1 616Medicaid directors suggested in a joint statement options to
address prices of expensive new pharmaceuticals [3]. In June
2015, the American Society of Clinical Oncology proposed a value
framework for comparing the relative clinical beneﬁt, toxicity,
and cost of cancer treatments (see Fig. 1: NYT, June 22, 2015).Strategies
Throughout the past 30 years, various stakeholders implemented
and suggested different strategies to cope with high-priced
medicines: 1) industry offered to reduce drug prices (see Fig. 1:
WSJ, September 19, 1989) as well as to distribute discount cards; 2)
states and federal government agencies mandated drug price dis-
counts for the Medicare Part D program, initiated lawsuits against
pharmaceutical companies for overcharging for medicines, and
mentioned importing of lower-priced drugs from abroad as well
as legal changes to allow for price negotiations and price controls
(see Fig. 1: WSJ, April 19, 2007); more recently, states have
introduced pharmaceutical cost transparency bills requiring the
pharmaceutical industry to justify drug pricing [4]; 3) payers have
typically responded to the introduction of expensive products by
limiting access through prior authorization, mandating the use of
generics, implementing different co-payment tiers, and shifting
an increasing proportion of costs to patients, through higher
insurance premiums and coinsurance, co-payments, and deduc-
tibles. The establishment of a buyer consortium through which
they could negotiate lower prices was also debated in media; 4)
patients shopped for cheaper medicines abroad or opted to forgo
treatment; 5) in 1993, experts mentioned the implementation of
cost-effectiveness analysis and price control regulations as pos-
sible ways forward. More recently, however, experts more
strongly call for ways to assess the overall value of a product.
They point to examples from Europe and Canada where decision
makers use multiple tools to negotiate prices, such as value-
based (health technology assessments, pharmacoeconomic anal-
yses), reference-based (international and therapeutic price refer-
encing), and risk-based (managed entry agreements) approaches.
As is the case in Europe and Canada, authors suggested using
quality-adjusted-life-years—a measure of the state of health of a
person or group that deﬁnes beneﬁts of products in terms of
length and quality of life—to assess beneﬁts of a product
compared to its price [5].Discussion
Our media search on “drug pricing” over the last 30 years showed
that high prices of medicines have been a hot topic for a long time.
US policymakers have historically been reluctant to embrace price
regulations, instead relying on market forces to set prices. In
addition, a drug’s value is not routinely considered. US drug prices
are among the highest worldwide and contribute to devastatingconsequences of care for patients as medical expenses remain the
most common cause of personal bankruptcy [6].
Our optimistic belief is that the recent groundswell of opinion
regarding high drug prices, in combination with a changing
environment, constitutes a “watershed moment” for legal and
policy innovations that provide payers the tools to ensure patient
access to effective treatments at affordable prices while continuing
to incentivize much-needed innovations. We suggest future
research to build on our brief summary of media coverage of drug
prices over time. Questions to address include the following: What
factors and which stakeholders have prompted media coverage?
Which policy and program actions have followed increasing media
discussion of drug prices? How can media coverage contribute to a
critical and constructive multistakeholder dialogue of health
technology innovations’ beneﬁts and costs?
In his 2015 State of the Union address, President Obama
committed to invest in basic and clinical research for personalized
and precision medicines. We strongly advocate for additional
funding of policy research to explore the ﬁnancial impacts of
innovations on patients, providers, payers, and the system as a
whole and to develop evidence for innovative pricing and reim-
bursement strategies. We believe that there will not be one single
approach to pricing and paying for innovations but rather multi-
faceted approaches that will need to consider not only safety,
efﬁcacy, and cost but also the overall societal value of innova-
tions. For true change, in our opinion, all stakeholders need to act
in concert to develop strategies that ensure investment in R&D
and guarantee long-term affordable access to needed innovations.
Source of ﬁnancial support: The authors have no other
ﬁnancial relationships to disclose.
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